Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2014-03-07

Last Posted Date: 2019-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 221228

Registration Number: NCT02081807

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809 PfOS
Drug: Placebo
Drug: BI 425809 tablet

First Posted Date: 2014-02-21

Last Posted Date: 2014-10-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT02068690

Locations: 🇩🇪
1346.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Observational

First Posted Date: 2014-02-13

Last Posted Date: 2017-06-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38499

Registration Number: NCT02061748

Locations: 🇺🇸
Comprehensive Health Insights, Louisville, Louisville, Kentucky, United States

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 691751
Drug: BI 691751 middle dose
Drug: BI 691751 low dose 2
Drug: BI 691751 low dose 1
Drug: BI 691751 high dose

First Posted Date: 2014-02-07

Last Posted Date: 2015-12-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02057835

Locations: 🇰🇷
1334.5.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BI 655066
Drug: Ustekinumab

First Posted Date: 2014-02-04

Last Posted Date: 2016-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 166

Registration Number: NCT02054481

Locations: 🇺🇸
1311.2.10011 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇸🇪
1311.2.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden
🇫🇷
1311.2.33005 Boehringer Ingelheim Investigational Site, Marseille, France

and more 29 locations

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib

First Posted Date: 2014-01-28

Last Posted Date: 2020-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 161

Registration Number: NCT02047903

Pharmacokinetics and Safety in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: adalimumab-US source
Drug: BI 695501
Drug: adalimumab-EU source

First Posted Date: 2014-01-27

Last Posted Date: 2018-06-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 327

Registration Number: NCT02045979

Locations: 🇧🇪
1297.8.1001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
🇳🇿
1297.8.2002 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand
🇳🇿
1297.8.2001 Boehringer Ingelheim Investigational Site, Auckland, New Zealand

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib

First Posted Date: 2014-01-24

Last Posted Date: 2017-03-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02044380

Locations: 🇨🇦
Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

Interaction of BI 691751 With Itraconazole

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 691751
Drug: itraconazole

First Posted Date: 2014-01-24

Last Posted Date: 2015-12-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02044393

Locations: 🇩🇪
1334.10.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1181181, R
Drug: BI 1181181
Drug: BI 1181181, T2
Drug: Placebo to BI 1181181
Drug: BI 1181181, T1

First Posted Date: 2014-01-24

Last Posted Date: 2014-10-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT02044406

Locations: 🇩🇪
1344.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy